Unum Therapeutics Inc (UMRX) Stock Fundamental Analysis

NASDAQ:UMRX

2.35
+0.01 (+0.43%)
Last: Oct 5, 2020, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
No Fundamental Analysis report for UMRX not available.

Unum Therapeutics Inc

NASDAQ:UMRX (10/5/2020, 8:00:05 PM)

2.35

+0.01 (+0.43%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0%
Inst Owner Change0%
Ins Owners34.59%
Ins Owner Change0%
Market Cap99.80M
Revenue(TTM)23.87M
Net Income(TTM)-23.11M
Analysts86.6
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.18
P/FCF N/A
P/OCF N/A
P/B 5.19
P/tB N/A
EV/EBITDA -3.78
EPS(TTM)-0.76
EYN/A
EPS(NY)-0.17
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.56
BVpS0.45
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -74.43%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -97.79%
PM (TTM) -96.84%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.9
Quick Ratio 2.9
Altman-Z -2.21
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.41%
EPS Next Y75%
EPS Next 2Y54.81%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)98.25%
Revenue growth 3YN/A
Revenue growth 5Y51.54%
Sales Q2Q%-83.17%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Unum Therapeutics Inc / UMRX FAQ

What is the ChartMill fundamental rating of Unum Therapeutics Inc (UMRX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to UMRX.


Can you provide the valuation status for Unum Therapeutics Inc?

ChartMill assigns a valuation rating of 1 / 10 to Unum Therapeutics Inc (UMRX). This can be considered as Overvalued.


How profitable is Unum Therapeutics Inc (UMRX) stock?

Unum Therapeutics Inc (UMRX) has a profitability rating of 2 / 10.


How sustainable is the dividend of Unum Therapeutics Inc (UMRX) stock?

The dividend rating of Unum Therapeutics Inc (UMRX) is 0 / 10 and the dividend payout ratio is 0%.